Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 3/20 | 0.31 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.30 |
| ▸ | MMP1 | P03956 | 2/20 | 0.30 |
| ▸ | MMP2 | P08253 | 2/20 | 0.30 |
| ▸ | MMP3 | P08254 | 2/20 | 0.30 |
| ▸ | MMP8 | P22894 | 2/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL29213143 | 0.82 | MMP1 (0.33) | MEN1KMT2ALMNAHPGDTSHR | |
| SCHEMBL17331124 | 0.82 | FDPS (0.41) | FDPSLPAR3LPAR2 | |
| SCHEMBL11041745 | 0.79 | LAP3 (0.34) | FDPSLAP3 | |
| SCHEMBL4267678 | 0.79 | FDPS (0.44) | FDPSLPAR3LPAR2 | |
| SCHEMBL6654898 | 0.77 | GRM4 (0.45) | MEN1KMT2ALMNAHPGDTSHR | |
| SCHEMBL173322 | 0.76 | FFAR3 (0.41) | MEN1KMT2ATSHRTDP1ALDH1A1 | |
| SCHEMBL1691821 | 0.76 | MMP1 (0.32) | ALDH1A1MMP1MMP2MMP3MMP8 | |
| SCHEMBL7612809 | 0.75 | FDPS (0.37) | LMNAFDPSLAP3LPAR3LPAR2 | |
| SCHEMBL11316221 | 0.74 | MMP2 (0.34) | MMP1MMP2MMP3MMP8MMP9 | |
| SCHEMBL710887 | 0.74 | CYP4F2 (0.50) | MEN1KMT2ALMNAALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240128511-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-04-18 | — | — | US | disclosed |
| US-11942601-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-03-26 | — | — | US | disclosed |
| US-11424482-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-08-23 | — | — | US | disclosed |
| US-20190334208-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-10-31 | — | — | US | disclosed |
| US-20150364794-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-12-17 | — | — | US | disclosed |
| US-7655624-B2 | Antiinflammatory agents; osteoporosis; cardiovascular disorders; coating for prosthetics | BIOMET DEUTSCHLAND GMBH (DE) | 2010-02-02 | — | — | US | disclosed |
| US-20040029782-A1 | Peptide and peptide mimetic conjugates with integrin-inhibitor properties | BIOMET DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | disclosed |
| EP-0871439-A4 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0871439-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029782-A1 | Peptide and peptide mimetic conjugates with integrin-inhibitor properties | ITGB1, ITGB2, ITGA1 | MEN1 1482/4885KMT2A 1916/4885LMNA 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.